News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

|Videos|November 24, 2020

Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

Author(s)Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC, Robert Naismith, MD, Bianca Weinstock-Guttman, MD

Episodes in this series

EP. 1 Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

EP. 1 Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

EP. 2 OLKIOS: Looking at Ofatumumab’s Continued Efficacy

EP. 2 OLKIOS: Looking at Ofatumumab’s Continued Efficacy

EP. 3 OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

EP. 3 OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

EP. 4 Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

EP. 4 Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

EP. 5 Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

EP. 5 Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

EP. 6 Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

EP. 6 Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

EP. 7 OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

EP. 7 OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

EP. 8 OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

EP. 8 OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

EP. 9 Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

EP. 9 Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

EP. 10 Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

EP. 10 Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

EP. 11 Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

EP. 11 Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

EP. 12 Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

EP. 12 Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

EP. 13 CLARITY Extension Trial: Disability Improvement With Cladribine

EP. 13 CLARITY Extension Trial: Disability Improvement With Cladribine

EP. 14 COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

EP. 14 COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

EP. 15 Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

EP. 15 Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

NeurologyLive® Year in Review 2025: Top Interviews on the AI Takeover

ByIsabella Ciccone, MPH

December 31st 2025

NeuroVoices: David A. Hafler, MD, FANA, on Understanding MS as an Autoimmune and Neurodegenerative Disease

ByIsabella Ciccone, MPH,David A. Hafler, MD, FANA

December 31st 2025

NeurologyLive® Year in Review 2025: Top trending Migraine Trials

ByNeurologyLive® Staff

December 30th 2025

NeurologyLive® Year in Review 2025: Spotlighting SAP Collaborations

ByIsabella Ciccone, MPH

December 30th 2025

NeurologyLive® Year in Review 2025: Most Impactful FDA Decisions

ByIsabella Ciccone, MPH

December 29th 2025

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

NeurologyLive® Year in Review 2025: Top Interviews on the AI Takeover

NeuroVoices: David A. Hafler, MD, FANA, on Understanding MS as an Autoimmune and Neurodegenerative Disease

NeurologyLive® Year in Review 2025: Top trending Migraine Trials

NeurologyLive® Year in Review 2025: Spotlighting SAP Collaborations

NeurologyLive® Year in Review 2025: Conference Coverage Recap